Anyone working within Global Portfolio Strategy, Commercial Capabilities, Operations or Strategy, or as a Chief Marketing Officer in the rare disease arena will understand the challenges faced when launching treatment effectively, due to fewer, and often geographically scattered patients. Finding rare condition patients, fostering treatment accessibility, and understanding uptake potential are top of the agenda when building a market expansion strategy to ensure that both patients are helped, and optimal return on investment is achieved.
A pharmaceutical company focused on the rare disease space approached IQVIA looking to do exactly this. Having decided to look for analogues and observe product uptake in different geographies to support their investment allocation for their company's geographic roll-out plan, they required specialist support to identify up to six ideal high-cost analogues.
Challenges
Overcoming these challenges required finding a way to estimate uptake for rare diseases. This needed to include speed of uptake, time to peak, patient adoption, patient days, reimbursement, label expansions, clinical factors, and more. The ability to benchmark their project against other historical rare disease analogues was also a key requirement.
Fill in your details on your left, to uncover the steps and key takeaways to success in this case study!
Analyze industry leading sales and medical data in a standardized and comparable way, including cross-country analysis of performance and additional insights into global and regional markets.
.svg){kind=icon}
